5,724 results match your criteria Annals of hematology[Journal]


Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial.

Ann Hematol 2019 Feb 20. Epub 2019 Feb 20.

Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1620, New York, NY, 10029-6574, USA.

Inhaled mometasone was shown to improve pain scores and decrease soluble vascular cell adhesion molecule (sVCAM) concentration in a randomized controlled trial of nonasthmatic patients with sickle cell disease. We sought to explore potential changes in systemic inflammation as a mechanism underlying this effect. Serum samples from 41 trial participants (15 placebo- and 26 mometasone-treated) were analyzed using a 92 inflammatory marker panel at baseline and after 8 weeks of mometasone therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03635-9DOI Listing
February 2019

Multiplex STR panel for assessment of chimerism following hematopoietic stem cell transplantation (HSCT).

Ann Hematol 2019 Feb 19. Epub 2019 Feb 19.

Hematology Unit, Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.

Short tandem repeat (STR) analysis is used in chimerism monitoring after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with various hematologic malignancies. Commercial forensic STR kits often contain loci with huge differences in power of discrimination (PD) across populations, causing some loci to be less informative for chimerism analysis in certain populations. This study aimed to construct a new STR multiplex panel with highly informative loci for efficient chimerism analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03626-wDOI Listing
February 2019

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Ann Hematol 2019 Feb 18. Epub 2019 Feb 18.

University of Toulouse III Paul Sabatier, Toulouse, France.

Delivering of > 80% planned relative dose intensity (RDI) of fludarabine-cyclophosphamide-rituximab (FCR) is key to benefit from longer progression free survival (PFS) and survivals in CLL. In this randomized trial, we sought to investigate whether a telephone intervention strategy (called AMA) delivered by an oncology nurse could reduce the risk of RDI < 80% by alleviating adverse events and supporting patients' adherence. Sixty FCR patients were randomized 1:1 for AMA (stratified on Binet stage C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03631-zDOI Listing
February 2019

Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.

Ann Hematol 2019 Feb 13. Epub 2019 Feb 13.

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03616-yDOI Listing
February 2019
1 Read

Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.

Ann Hematol 2019 Feb 13. Epub 2019 Feb 13.

Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA.

t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is a rare recurrent cytogenetic abnormality associated with acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03637-7DOI Listing
February 2019
1 Read

Different prognostic effects of core-binding factor positive AML with Korean AML registry data.

Ann Hematol 2019 Feb 13. Epub 2019 Feb 13.

Division of Hematology, Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Republic of Korea.

Core-binding factor acute myeloid leukemia (CBF-AML) data in Asian countries has been rarely reported. We analyzed 392 patients with CBF-AML [281 with t(8;21), 111 with inv.(16)/t(16;16)] among data from 3041 patients with AML from the Korean AML Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03624-yDOI Listing
February 2019
1 Read

Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.

Donor lymphocyte infusion (DLI) might be used prophylactically to reduce relapse after allogeneic hematopoietic stem cell transplantation for very high-risk leukemia/lymphoma without effective targeted therapy. To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective analysis in a cohort of 21 HID-SCT and 13 MSD-SCT recipients, displaying similar baseline characteristics except for donor's gender distribution. Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03636-8DOI Listing
February 2019
2 Reads

A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Division of Hematology, Department of Medicine and Duke Cancer Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03632-yDOI Listing
February 2019

Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Department of Molecular and Internal Medicine, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03638-6DOI Listing
February 2019
1 Read

A case report of congenital erythropoietic anemia II in China with a novel mutation.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Department of Pediatrics, the Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03612-2DOI Listing
February 2019

ACUTE LEUKEMIAS XVII Biology and Treatment Strategies.

Authors:

Ann Hematol 2019 Feb;98(Suppl 1):1-75

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03619-9DOI Listing
February 2019

Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.

Ann Hematol 2019 Feb 7. Epub 2019 Feb 7.

Department of Pathology, Kurume University, School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.

The hepatitis C virus (HCV) is a single-stranded RNA virus which is thought to be involved in the onset of B cell lymphoma. HCV-positive diffuse large B cell lymphoma (DLBCL) has been reported to clinically manifest in extranodal lesions (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03628-8DOI Listing
February 2019
1 Read

Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis.

Ann Hematol 2019 Feb 7. Epub 2019 Feb 7.

Cardiovascular Diseases Research Center & Dep. of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

Despite the major improvement in therapeutic management of thalassemia major, iron overload is considered a challenging conundrum in these patients and heart disease still remains a major cause of morbidity and mortality in these patients. Therefore, this study aimed to investigate the prevalence of cardiac iron overload and cardiovascular complications in transfusion-dependent thalassemia patients in the worldwide. The following databases were searched: ISI/Web of Science, Embase, PubMed, Scopus, up to February 30, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03618-wDOI Listing
February 2019
1 Read

The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma.

Ann Hematol 2019 Feb 6. Epub 2019 Feb 6.

Department of Hematology, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, China.

To investigate the possible role of functional single nucleotide polymorphism (SNP) in circadian genes as prognostic markers of primary central nervous system lymphoma (PCNSL). We conducted a prospective study using data from Huashan Hospital 2006-2015 and followed up 91 PCNSL patients until June 30, 2016. The survival of patients with different prognostic factors was compared by log-rank test. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03629-7
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03629-7DOI Listing
February 2019
5 Reads

Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.

Ann Hematol 2019 Feb 6. Epub 2019 Feb 6.

Cedars-Sinai Medical Center, Los Angeles, USA.

In previous observational studies, we have separately characterized patients with multiple myeloma (MM) both from Latin America (LA) and from Asia. Here, we analyze these two datasets jointly, in order to assess the overall survival (OS) in these two world regions. Data were available from 3664 patients (1968 from LA and 1696 from Asia); all of whom diagnosed between 1998 and 2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03602-4DOI Listing
February 2019
8 Reads

Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients.

Ann Hematol 2019 Feb 5. Epub 2019 Feb 5.

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03630-0DOI Listing
February 2019
2 Reads
2.634 Impact Factor

Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.

Ann Hematol 2019 Feb 5. Epub 2019 Feb 5.

Department of Hematology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

The aim of our study was to evaluate the prognostic impact of minimal residual disease (MRD) and high-risk cytogenetics (HRCs) on outcomes in multiple myeloma (MM) patients. We applied multiparameter flow cytometry (MFC) to detect MRD in 123 consecutive patients diagnosed with MM for the first time who achieved very good partial remission (VGPR) or better after bortezomib or thalidomide-based induction therapy. Moreover, we examined the cytogenetic features of MM patients using magnetic-activated cell sorting and interphase fluorescence in situ hybridization (MACS-iFISH) at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03609-xDOI Listing
February 2019
2.634 Impact Factor

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.

Ann Hematol 2019 Feb 5. Epub 2019 Feb 5.

School of Life Sciences, College of Science, Joseph Banks Laboratories, University of Lincoln, Green Lane, Lincoln, Lincolnshire, LN6 7DL, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03627-9DOI Listing
February 2019
1 Read

Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.

Ann Hematol 2019 Feb 4. Epub 2019 Feb 4.

Jiangsu Institute of Haematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Epstein-Barr virus (EBV) reactivation is a life-threatening complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT). In this study, we investigated the characteristics of EBV reactivation in 186 consecutive myelodysplastic (MDS) patients who underwent allo-HSCT in our centre. In 35 patients (18. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03603-3
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03603-3DOI Listing
February 2019
2 Reads

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma.

Ann Hematol 2019 Feb 4. Epub 2019 Feb 4.

Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, People's Republic of China.

To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high-dose etoposide for stem cell mobilization. All patients were in progressive disease (PD) prior to mobilization and underwent high-dose chemotherapy followed by APBSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03605-1DOI Listing
February 2019
1 Read

Inhibitor eradication in refractory acquired hemophilia with lenalidomide.

Ann Hematol 2019 Feb 1. Epub 2019 Feb 1.

Division of Hemostaseology, University Hospital Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03620-2DOI Listing
February 2019
1 Read

Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.

Ann Hematol 2019 Jan 29. Epub 2019 Jan 29.

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, 560029, India.

Elderly patients with acute myeloid leukemia have a poor prognosis. Data from developing countries is sparse in the literature. In this retrospective study, 402 patients aged ≥ 60 years, diagnosed between Jan 2013 and Dec 2017, were analyzed for treatment patterns and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03600-6DOI Listing
January 2019
2 Reads

Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm.

Ann Hematol 2019 Jan 29. Epub 2019 Jan 29.

Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang, Wuhou District Cancer Center, Chengdu, 610041, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03623-zDOI Listing
January 2019
1 Read

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey.

Ann Hematol 2019 Jan 29. Epub 2019 Jan 29.

UT Health San Antonio Cancer Center, San Antonio, TX, USA.

Patients with myeloproliferative neoplasms (MPNs) experience burdensome symptoms that negatively affect their quality of life. How MPN symptoms relate with medical disability leave (MDL) among patients with the disease has not been previously examined. Using data collected from the Living with MPNs patient survey, symptom burden and functional status were compared in patients who reported taking MDL due to their MPN versus patients who reported no changes in employment status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03610-4DOI Listing
January 2019
1 Read

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.

Ann Hematol 2019 Jan 28. Epub 2019 Jan 28.

Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.

Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-03592-9DOI Listing
January 2019
1 Read

Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.

Ann Hematol 2019 Mar 25;98(3):775-779. Epub 2019 Jan 25.

Infectious Diseases Unit, 1st Department of Paediatrics, Aghia Sofia Children's Hospital, National and Kapodistrian University of Athens, Thivon & Levadias Str, 115 27, Athens, Greece.

Streptococcus pnemoniae is a major cause of morbidity and mortality among splenectomised patients with β-thalassemia major. We have previously shown that a 13-valent pneumococcal conjugate vaccine (PCV13) induces robust early immune responses in such patients, while history of repeated immunisations with the 23-valent polysaccharide pneumococcal vaccine (PPSV23) results in attenuation of the response to PCV13. However, the duration of vaccine-induced protection in splenectomised thalassemic patients and the associated need for booster immunisation remains unclear. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03615-z
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03615-zDOI Listing
March 2019
3 Reads

Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders.

Ann Hematol 2019 Mar 25;98(3):625-632. Epub 2019 Jan 25.

Department of Internal Medicine II: Hematology and Oncology, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Post-transplant lymphoproliferative disease (PTLD) is a serious complication of solid organ transplantation. As early diagnosis remains challenging, we investigated the utility of serum-free light chain (FLC) and heavy chain/light chain pairs (HLC) as diagnostic biomarkers. Pre-treatment serum FLC and HLC levels were measured in 20 patients at their first diagnosis of B cell PTLD and in 14/20 patients during follow-up. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-03591-w
Publisher Site
http://dx.doi.org/10.1007/s00277-018-03591-wDOI Listing
March 2019
8 Reads

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.

Ann Hematol 2019 Mar 24;98(3):713-722. Epub 2019 Jan 24.

Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Infections represent a major cause of morbidity and mortality in multiple myeloma and are linked to both therapy- and disease-related factors. Although it has been suggested that the rate of infections increased since the introduction of novel agents, controversies still exist. To better assess the risk factors associated with infections in the era of novel agents, we conducted a large retrospective analysis of 479 myeloma patients treated at Jena University Hospital over a period of 12 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03621-1DOI Listing
March 2019
1 Read

Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myeloma.

Ann Hematol 2019 Mar 23;98(3):705-711. Epub 2019 Jan 23.

Hematology Department, Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universidad Autónoma de Barcelona, Barcelona, Spain.

The availability of new agents for the treatment of multiple myeloma has allowed the use of multiple lines of treatment, but a percentage of patients do not reach to receive this combination because of toxicity and early death. In this regard, a cross-sectional European study evaluated the management of different lines and discontinuation of treatment in 7635 patients from seven countries in routine clinical practice, finding that 39% of European patients do not receive a second line and that only 4% of patients reach third line in Spain, a figure that is striking when comparing with the rest of the countries. We analyze the frequency and causes of treatment discontinuation in a series of 108 patients from a Spanish University hospital showing that the main reason for permanent treatment discontinuation after finishing first line was to have a response, while death due to disease progression accounted for the main reason in subsequent lines of therapy, with its frequency increasing according to the number of lines received. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03601-5DOI Listing
March 2019
1 Read

Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.

Ann Hematol 2019 Mar 23;98(3):595-603. Epub 2019 Jan 23.

Department of Pediatric Hematology and Oncology, University Hospital Essen, Hufelandstraße 55, D-45147, Essen, Germany.

Despite high remission rates, almost 25% of patients with AML will suffer relapse 3-5 years after diagnosis. Therefore, in addition to existing diagnostic and MRD detection tools, there is still a need for the development of novel approaches that can provide information on the state of the disease. Extracellular vesicles (EVs), containing genetic material reflecting the status of the parental cell, have gained interest in recent years as potential diagnostic biomarkers in cancer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03608-y
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03608-yDOI Listing
March 2019
2 Reads

Severe hemolytic anemia due to combined α thalassemia and de novo Hemoglobin Sabine.

Ann Hematol 2019 Mar 23;98(3):783-785. Epub 2019 Jan 23.

Department of Central Laboratory, Key Laboratory of Cellular and Molecular Genetic Transformation of Hainan Province Medicine, Hainan Province People's Hospital, Haikou, 570311, Hainan Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03617-xDOI Listing
March 2019
2 Reads

Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies.

Ann Hematol 2019 Jan 21. Epub 2019 Jan 21.

Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.

Cytomegalovirus (CMV) infection and primary disease relapse remain challenging problems after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We sought to assess the association between CMV infection and disease relapse after transplantation. PubMed, EMBASE, the Cochrane Library, SCI, and Chinese Biomedicine Databases were searched up to July 1, 2018, for all studies that investigate pre-transplant CMV serostatus, CMV replication, and primary disease relapse in allo-HSCT patients with hematologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3585-1DOI Listing
January 2019
3 Reads
2.634 Impact Factor

Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases.

Ann Hematol 2019 Mar 21;98(3):763-773. Epub 2019 Jan 21.

Department of Hematology and Oncology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Enterococcus species are commensals of the human gastrointestinal tract with the ability to cause invasive infections. For patients with hematological diseases, enterococcal bloodstream infections (BSI) constitute a serious clinical complication which may even be aggravated if the pathogen is vancomycin-resistant. Therefore, we analyzed the course of BSI due to vancomycin-susceptible enterococci (VSE) in comparison to vancomycin-resistant enterococci (VRE) on patient survival. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03607-z
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03607-zDOI Listing
March 2019
3 Reads

The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.

Ann Hematol 2019 Mar 21;98(3):745-752. Epub 2019 Jan 21.

Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.

Hepatic veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). We conducted this study to investigate the incidence and risk factors of hepatic VOD for patients receiving HSCT in Taiwan. We retrospectively analyzed the data from a nationwide registry for patients receiving HSCT, which was collected by the Taiwan Society of Blood and Marrow Transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03604-2DOI Listing
March 2019
2 Reads

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.

Ann Hematol 2019 Mar 21;98(3):541-559. Epub 2019 Jan 21.

Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Drive, Room CW 7-251B, Ann Arbor, MI, 48109-2054, USA.

Secondary AML is associated with a disproportionately poor prognosis, consistently shown to exhibit inferior response rates, event-free survival, and overall survival in comparison with de novo AML. Secondary AML may arise from the evolution of an antecedent hematologic disorder, or it may arise as a complication of prior cytotoxic chemotherapy or radiation therapy in the case of therapy-related AML. Because of the high frequency of poor-risk cytogenetics and high-risk molecular features, such as alterations in TP53, leukemic clones are often inherently chemoresistant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03606-0DOI Listing
March 2019
2.634 Impact Factor

Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.

Ann Hematol 2019 Mar 18;98(3):787-788. Epub 2019 Jan 18.

Department of Hematology, Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03613-1DOI Listing
March 2019
5 Reads

Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.

Ann Hematol 2019 Mar 16;98(3):801-803. Epub 2019 Jan 16.

Division of Hematology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-0072, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03611-3DOI Listing
March 2019
1 Read

Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.

Ann Hematol 2019 Mar 15;98(3):793-795. Epub 2019 Jan 15.

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03614-0DOI Listing
March 2019
2 Reads

Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation.

Ann Hematol 2019 Mar 14;98(3):789-791. Epub 2019 Jan 14.

Department I of Internal Medicine, Critical Care Medicine, University Hospital of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03596-zDOI Listing
March 2019
1 Read

Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.

Ann Hematol 2019 Jan 12. Epub 2019 Jan 12.

Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.

The aim of this study is to determine whether the modified BuCy (semustine, cytarabine, busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an alternative to the SEAM (semustine, etoposide, cytarabine, and melphalan) regimen by comparing the efficacy and toxicity of the mBuCy and SEAM regimens. We matched 34 pairs of patients with regard to disease status at the time of autologous stem cell transplantation (auto-SCT). We found no significant difference in the time of platelet engraftment between the two groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3576-2DOI Listing
January 2019
2 Reads

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.

Ann Hematol 2019 Mar 11;98(3):691-703. Epub 2019 Jan 11.

Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA.

The Janus kinase (JAK) pathway has been shown to play key roles in the growth and resistance to drugs that develop in multiple myeloma (MM) patients. The anti-MM effects of the selective JAK1 inhibitor INCB052793 (INCB) alone and in combination with anti-MM agents were evaluated in vitro and in vivo. Significant inhibition of cell viability of primary MM cells obtained fresh from MM patients, and the MM cell lines RPMI8226 and U266, was observed with single agent INCB and was enhanced in combination with other anti-MM agents including proteasome inhibitors and glucocorticosteroids. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03595-0
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03595-0DOI Listing
March 2019
14 Reads

Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.

Ann Hematol 2019 Mar 11;98(3):633-645. Epub 2019 Jan 11.

Luekemia Center, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, 300020, China.

The aim of this study is to investigate the efficacy and safety of nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Thirty patients with Ph+ ALL were recruited. Standard induction chemotherapy was given for 4 weeks. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03594-1
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03594-1DOI Listing
March 2019
7 Reads
2.634 Impact Factor

HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia.

Ann Hematol 2019 Jan 10. Epub 2019 Jan 10.

Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, People's Republic of China.

HLA-mismatched stem cell microtransplantation is a new form of transplantation reported in recent years. We compared 59 patients undergoing microtransplantation to 66 patients undergoing HLA-matched sibling donor (MSD) transplantation at the same period from April 2012 to December 2016, who all suffered from intermediate/high-risk acute myelogenous leukemia (AML) in first complete remission (CR1). The estimated overall survival (OS) at 2 years was 74. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3583-3
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3583-3DOI Listing
January 2019
9 Reads

Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.

Ann Hematol 2019 Mar 8;98(3):753-762. Epub 2019 Jan 8.

Department of Medicine III, Stem Cell Transplantation Unit, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.

In acute myeloid leukemia (AML), primary refractory or relapsed disease, secondary AML, and leukemia with unfavorable genetics are considered high-risk AML (hrAML), with allogeneic stem cell transplantation (SCT) representing the standard treatment. Sequential conditioning has been successfully used for SCT in hrAML in HLA-matched transplants, and found its way into HLA-haploidentical SCT (haplo-SCT) later on. Hence, sequential conditioning had become standard for all patients with hrAML in our two centers, regardless of donor type. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03593-2
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03593-2DOI Listing
March 2019
4 Reads

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 Jan 8. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age ≥ 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3571-7
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3571-7DOI Listing
January 2019
8 Reads

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.

Ann Hematol 2019 Mar 6;98(3):647-656. Epub 2019 Jan 6.

Department of Hematology and Oncology, Johann Wolfgang Goethe University of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany.

The 2016 revised World Health Organization (WHO) classification of lymphoid neoplasms included the category of high-grade B cell lymphomas (HGBLs) with combined MYC and BCL2 and/or BCL6 rearrangements (double-hit, DH). However, the clinical features of B cell precursor leukemia (BCP-ALL) that harbor DH genetics remain widely unknown. We performed a retrospective analysis of the German Multicenter Study Group for Adult ALL registry and a literature search for de novo DH-BCP-ALLs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-03590-x
Publisher Site
http://dx.doi.org/10.1007/s00277-018-03590-xDOI Listing
March 2019
5 Reads

Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.

Ann Hematol 2019 Mar 5;98(3):735-743. Epub 2019 Jan 5.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

The diagnosis of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome requires polyneuropathy and monoclonal plasma cell proliferation as two mandatory criteria. Our aim was to summarize clinical manifestations and treatment responses of POEMS variants with no evidence of monoclonal gammopathy. We queried all medical documentation of patients referred to Peking Union Medical College Hospital from August 2012 to July 2017, and reviewed the clinical and laboratory features of 13 patients with atypical POEMS syndrome with undetectable monoclonal gammopathy, and compared to prototypes published. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-03589-4
Publisher Site
http://dx.doi.org/10.1007/s00277-018-03589-4DOI Listing
March 2019
8 Reads

Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.

Ann Hematol 2019 Jan 4. Epub 2019 Jan 4.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Dadao, Wuhan, 430022, China.

Immunoglobulin D (IgD) myeloma is a rare subtype that used to lead to a poor outcome. To investigate the current clinical features, cytogenetic changes and survival of patients with IgD myeloma under novel treatments, we analysed 47 patients with IgD myeloma, 31 men and 16 women, with a median age of 54.5 years. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3582-4
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3582-4DOI Listing
January 2019
7 Reads